AgonOx, Inc. develops novel therapies to treat cancer patients. The research strategy at AgonOx focuses on the interaction between T cells and tumor cells. Using bioinformatics, in-vitro, and in-vivo testing to identify and validate new therapeutic approaches. AgonOx conducts its research in laboratories at the Portland Providence Cancer Center where staff scientists work closely with oncologists, surgeons, and immunologists. This collaboration has led to two first-in-human clinical trials with the latest commencing in August 2023. The company’s focus in recent years has been utilizing selected tumor-reactive T cells in adoptive cell therapy for the treatment of patients with solid malignancies.
Company Details
- Employees
- 6
- Founded
- -
- Address
- Portland, Oregon
- Industry
- Biotechnology
- Website
- agonox.com
- Keywords
- Cancer immunotherapy, Immunology, Drug discovery, Oncology, Cancer research, T cell based immunotherapy, Combination treatments, Immune phenotyping.
- HQ
- Portland, Oregon
Agonox, Inc. Questions
Agonox, Inc.'s website is agonox.com
Agonox, Inc.'s LinkedIn profile is https://www.linkedin.com/company/agonox-inc-
Agonox, Inc. has
6 employees.
View email and phone details for 6
employees at Agonox, Inc..
Agonox, Inc.'s industry is
Biotechnology
Agonox, Inc.'s top competitors are
Ubivac,
Trace Biosciences,
Therafluor Inc,
Sparrow Pharmaceuticals, Inc.,
Invivo Biosystems,
Veana Therapeutics, Llc.,
Pdx Pharmaceuticals,
Aronora,
Nobilis Therapeutics,
Sedia Biosciences Corp..
Agonox, Inc.'s categories are Biotechnology
Agonox, Inc.'s founding year is 2012
